Expression and its clinical significance of mammalian target of rapamycin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine neoplasm

被引：0
|
作者：
陈洁 [1 ]
机构：
[1] Dept Gastroenterol,1st Affil Hosp,Sun Yat-sen Univ
来源：
China Medical Abstracts(Internal Medicine) | 2014年 / 31卷 / 03期
关键词：
GEP; VEGF; Expression and its clinical significance of mammalian target of rapamycin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine neoplasm;
D O I：
暂无
中图分类号：
R735.35 [];
学科分类号：
100214 ;
摘要：
Objective To explore the expression,correlation and clinical significance of mammalian target of rapamycin(mT OR)and vascular endothelial growth factor(VEGF)in gastroenteropancreatic neuroendocrine neoplasm(GEP-NEN).Methods From October 1995 to December 2012,the paraffin tissue specimens of 114 pathological diagnosed GEP-NEN were collected.The expressions of mT OR and VEGF at protein level were detected
引用
收藏
页码：175 / 176
页数：2
相关论文
共 50 条
  • [1] Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms
    Zhang, Y.
    Chen, L.
    Lin, Y.
    Chen, M.
    Chen, J.
    NEUROENDOCRINOLOGY, 2018, 106 : 21 - 21
  • [2] Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
    Takashi Shida
    Takashi Kishimoto
    Mitsuko Furuya
    Takashi Nikaido
    Keiji Koda
    Shigetsugu Takano
    Fumio Kimura
    Hiroaki Shimizu
    Hiroyuki Yoshidome
    Masayuki Ohtsuka
    Tohru Tanizawa
    Yukio Nakatani
    Masaru Miyazaki
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 889 - 893
  • [3] Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
    Shida, Takashi
    Kishimoto, Takashi
    Furuya, Mitsuko
    Nikaido, Takashi
    Koda, Keiji
    Takano, Shigetsugu
    Kimura, Fumio
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Ohtsuka, Masayuki
    Tanizawa, Tohru
    Nakatani, Yukio
    Miyazaki, Masaru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (05) : 889 - 893
  • [4] Expression of an Activated Mammalian Target of Rapamycin (mTOR) in Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs)
    Dhall, D.
    Bose, S.
    MODERN PATHOLOGY, 2011, 24 : 135A - 135A
  • [5] Expression of an Activated Mammalian Target of Rapamycin (mTOR) in Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs)
    Dhall, D.
    Bose, S.
    LABORATORY INVESTIGATION, 2011, 91 : 135A - 135A
  • [6] Expression and Clinical Significance of Alpha-Internexin in Gastroenteropancreatic Neuroendocrine Neoplasm
    Yuhong, W.
    Yuan-Jia, C.
    Minhu, C.
    Jie, C.
    NEUROENDOCRINOLOGY, 2016, 103 : 53 - 53
  • [7] Combined Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor Pathway Inhibition in Pancreatic Neuroendocrine Tumors: More Than the Sum of Its Parts?
    Bergsland, Emily K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (14) : 1523 - +
  • [8] Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms
    Zhang, Y.
    Chen, L.
    Lin, Y.
    Chen, M.
    Chen, J.
    NEUROENDOCRINOLOGY, 2018, 106 : 22 - 22
  • [9] Prevalence and Clinical Significance of Mammalian Target of Rapamycin Phosphorylation (p-mTOR) and Vascular Endothelial Growth Factor (VEGF) in Clear Cell Carcinoma of the Ovary
    Khemapech, Nipon
    Pitchaiprasert, Sunaree
    Triratanachat, Surang
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6357 - 6362
  • [10] Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2
    Molhoek, Kerrington R.
    Griesemann, Heinrich
    Shu, Jianfen
    Gershenwald, Jeffrey E.
    Brautigan, David L.
    Slingluff, Craig L., Jr.
    CANCER RESEARCH, 2008, 68 (11) : 4392 - 4397
12345